Santhera Pharmaceuticals Holding AG/€SANN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG is a Swiss pharmaceutical company focused on the development and commercialization of innovative treatments for rare and debilitating diseases. The company's key areas of expertise include neuromuscular and pulmonary disorders. Santhera's product pipeline features several investigational drugs targeting conditions such as Duchenne muscular dystrophy and cystic fibrosis. Headquartered in Pratteln, Switzerland, the company leverages its scientific expertise and industry partnerships to advance its therapeutic offerings. Santhera's strategic focus on niche markets allows it to address unmet medical needs, providing potential opportunities for growth within specialized segments of the healthcare industry.
Ticker
€SANN
Sector
Primary listing
XSWX
Employees
79
Headquarters
Pratteln, Switzerland
Website
SANN Metrics
BasicAdvanced
€198M
-
-€3.93
-0.39
-
Price and volume
Market cap
€198M
Beta
-0.39
52-week high
€18.80
52-week low
€7.71
Average daily volume
23K
Financial strength
Current ratio
1.643
Quick ratio
1.188
Long term debt to equity
121.558
Total debt to equity
146.653
Interest coverage (TTM)
-4.26%
Profitability
EBITDA (TTM)
-29.795
Gross margin (TTM)
60.29%
Net profit margin (TTM)
-107.30%
Operating margin (TTM)
-84.75%
Effective tax rate (TTM)
-0.75%
Revenue per employee (TTM)
€532,180
Management effectiveness
Return on assets (TTM)
-15.81%
Return on equity (TTM)
-95.79%
Valuation
Price to revenue (TTM)
4.215
Price to book
6.69
Price to tangible book (TTM)
-4.49
Price to free cash flow (TTM)
-4.621
Free cash flow yield (TTM)
-21.64%
Free cash flow per share (TTM)
-3.335
Growth
Revenue change (TTM)
-62.17%
Earnings per share change (TTM)
-173.65%
3-year revenue growth (CAGR)
190.54%
10-year revenue growth (CAGR)
31.19%
3-year earnings per share growth (CAGR)
-38.99%
10-year earnings per share growth (CAGR)
-14.12%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Santhera Pharmaceuticals Holding AG stock?
Santhera Pharmaceuticals Holding AG (SANN) has a market cap of €198M as of August 24, 2025.
What is the P/E ratio for Santhera Pharmaceuticals Holding AG stock?
The price to earnings (P/E) ratio for Santhera Pharmaceuticals Holding AG (SANN) stock is 0 as of August 24, 2025.
Does Santhera Pharmaceuticals Holding AG stock pay dividends?
No, Santhera Pharmaceuticals Holding AG (SANN) stock does not pay dividends to its shareholders as of August 24, 2025.
When is the next Santhera Pharmaceuticals Holding AG dividend payment date?
Santhera Pharmaceuticals Holding AG (SANN) stock does not pay dividends to its shareholders.
What is the beta indicator for Santhera Pharmaceuticals Holding AG?
Santhera Pharmaceuticals Holding AG (SANN) has a beta rating of -0.39. This means that it has an inverse relation to market volatility.